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The Proton Pump Inhibitor Lansoprazole Improves the
Skeletal Phenotype in Dystrophin Deficient mdx Mice
Arpana Sali1, Gina M. Many1, Heather Gordish-Dressman1, Jack H. van der Meulen1, Aditi Phadke1,
Christopher F. Spurney1,2, Avital Cnaan1, Eric P. Hoffman1, Kanneboyina Nagaraju1*
1 Center for Genetic Medicine Research, Children’s National Medical Center, Department of Integrative Systems Biology, George Washington University School of Medicine
and Health Sciences, Washington, DC, United States of America, 2 Division of Cardiology, Children’s National Medical Center, Washington, DC, United States of America

Abstract
Background: In Duchenne muscular dystrophy (DMD), loss of the membrane stabilizing protein dystrophin results in
myofiber damage. Microinjury to dystrophic myofibers also causes secondary imbalances in sarcolemmic ion permeability
and resting membrane potential, which modifies excitation-contraction coupling and increases proinflammatory/apoptotic
signaling cascades. Although glucocorticoids remain the standard of care for the treatment of DMD, there is a need to
investigate the efficacy of other pharmacological agents targeting the involvement of imbalances in ion flux on dystrophic
pathology.
Methodology/Principal Findings: We designed a preclinical trial to investigate the effects of lansoprazole (LANZO)
administration, a proton pump inhibitor, on the dystrophic muscle phenotype in dystrophin deficient (mdx) mice. Eight to
ten week-old female mice were assigned to one of four treatment groups (n = 12 per group): (1) vehicle control; (2) 5 mg/
kg/day LANZO; (3) 5 mg/kg/day prednisolone; and (4) combined treatment of 5 mg/kg/day prednisolone (PRED) and 5 mg/
kg/day LANZO. Treatment was administered orally 5 d/wk for 3 months. At the end of the study, behavioral (Digiscan) and
functional outcomes (grip strength and Rotarod) were assessed prior to sacrifice. After sacrifice, body, tissue and organ
masses, muscle histology, in vitro muscle force, and creatine kinase levels were measured. Mice in the combined treatment
groups displayed significant reductions in the number of degenerating muscle fibers and number of inflammatory foci per
muscle field relative to vehicle control. Additionally, mice in the combined treatment group displayed less of a decline in
normalized forelimb and hindlimb grip strength and declines in in vitro EDL force after repeated eccentric contractions.
Conclusions/Significance: Together our findings suggest that combined treatment of LANZO and prednisolone attenuates
some components of dystrophic pathology in mdx mice. Our findings warrant future investigation of the clinical efficacy of
LANZO and prednisolone combined treatment regimens in dystrophic pathology.
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muscle function. Further, increases in intracellular Ca2+ levels
within dystrophic fibers induce myofiber necrosis via increasing
protease activity [7].
The progression of dystrophic pathology occurs as multiple
mechanical and inflammatory insults contribute to chronic
degeneration-regeneration remodeling cycles. Therapies aimed
at reducing muscle inflammation, i.e. glucocorticoids, remain the
standard-of-care for dystrophic pathology. Despite the acknowledged efficacy and widespread use of glucocorticoids, they do not
fully ameliorate dystrophic pathology. Diets high in NaCl have
been shown to attenuate myofiber necrosis and serum creatine
kinase levels in mdx mice [8], suggesting that manipulation of
systemic ion concentration gradients may help alleviate dystrophic
pathology. This data also suggests a need to investigate the

Introduction
Dystrophin is located in the cytoplasmic portion of the
sarcolemma and aids in muscle membrane stability and structural
integrity. Dystrophin and other proteins of the dystrophinassociated complex serve as scaffolding proteins that regulate the
association of proteins, such as ion channels, with the sarcolemma.
Loss of dystrophin is thought to destabilize the myofiber
membrane, in part, by altering the flux of ions and other proteins
through the sarcolemma [1]. This is supported by observations of
altered intracellular concentrations of Ca2+ [2], Mg2+ [2], K+ [3],
and Na+ [4] within dystrophic myofibers. Such alterations in
intracellular ion concentrations likely contribute to reductions in
resting membrane potential, membrane resistivity, and excitability
[5,6] observed in in dystrophic myofibers, which negatively affects
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Veh vs. PRED (p = 0.038); cVeh vs. Combined
(p = 0.007); abLANZO vs. PRED (p = 0.021);
ac
LANZO vs. Combined (p = 0.003)
Footnotes:
*Body mass was significantly different between groups at baseline, therefore, baseline body mass was included as a covariate in ANOVA modeling.
#
Two of the mice in the vehicle control group died before the time of sacrifice and thus 10 mice were analyzed at study completion in the untreated group.
¥
The muscle weights presented represent average weight between right and left muscle groups.
doi:10.1371/journal.pone.0066617.t001
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saline solution (0.9% NaCl, the vehicle used for LANZO
administration); (b) experimental group treated with 5 mg/kg/
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guidelines (Protocol # 1206) and thereby all animals were treated
according to local IACUC standards. C57BL/10ScSn-Dmdmdx/
J (mdx) 8–10 week-old female mice were purchased from Jackson
Laboratories (Bar Harbor, ME). All mice were acclimated for
7 days prior to study initiation and individually housed in a vented
cage system with 12 h alternating light-dark cycles. Mice received
standard mouse chow and purified water ad libitum.

Tissue Weight

Animal Care

LANZO

Materials and Methods
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Table 1. Comparison of muscle and organ weights between treatment groups at time of sacrifice.

Combined

Overall
p-value

Significantly different means

therapeutic efficacy of compounds capable of altering sarcolemmic
ion flux.
Lansoprazole, 2-[(4-trifluoroethoxy-3-methyl-2-pyridyl)methylsulfinyl]-1H-benzimidazole, is a 369.36 kDa substituted benzimidazole that acts as a gastric proton pump inhibitor (PPI).
Lansoprazole (LANZO) reduces stomach acidity by binding to
hydrogen-potassium adenosine triphosphatase (H+/K+-ATPase)
pumps located on the apical surface of gastric parietal cells.
LANZO H+/K+-ATPase binding inhibits parietal cell secretion of
hydrogen ions into the gastric cavity. LANZO is widely used in the
treatment of gastroesophageal reflux disease (GERD) and peptic
ulcers. In addition to reducing gastric acidity, LANZO has been
observed to attenuate inflammation in the gastric mucosa [9,10]
and inhibit nitric oxide (NO) [11] production by macrophages,
suggesting that an additional mechanism of LANZO action in the
gut may include its anti-inflammatory properties. A similar PPI,
omeprazole, has been shown to decrease the activity of immune
cells in the peripheral blood after oral administration in healthy
human subjects [11], suggesting LANZO may act systemically to
attenuate inflammation. Inflammation is a major component of
the dystrophic phenotypic in mdx mice and proinflammatory
macrophage accumulation has been shown to lyse dystrophic
fibers in an NO-dependent manner [12]. We thus sought to
investigate the effects of this proton pump inhibitor on the skeletal
muscle phenotype in mdx mice. We hypothesized that LANZO
administration would attenuate the dystrophic skeletal muscle
phenotype via altering ion influx and attenuating proinflammatory
and apoptotic signaling cascades underlying the dystrophic
pathology.
In this study, eight to ten week-old mdx mice were orally dosed
with a saline vehicle control, LANZO, prednisolone, or a
combined treatment regimen to determine the therapeutic efficacy
of each treatment. After three months of treatment, dual LANZO
and prednisolone administration was found to reduce serum
creatine kinase levels, the number of degenerating muscle fibers,
and the number of gastrocnemius inflammatory foci. Combined
treatment of LANZO and prednisolone also improved in vitro and
in vivo muscle force relative to vehicle control. Findings from our
study, thus, warrant future investigation of the therapeutic efficacy
of combined glucocorticoid and LANZO treatment regimens in
the treatment of dystrophic pathology.

None
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Figure 1. Effect of treatment on in vitro muscle force. The maximal (A) and specific (B) EDL muscle force was compared between vehicle
control (n = 8), LANZO (n = 7), prednisolone (n = 8), and combined treatment groups (n = 9). The percent differences in maximal or specific force
relative to vehicle control are presented above the error bars. No statistically significant differences in maximal muscle force were detected within
treatment groups. There were statistically significant within group differences in specific muscle force (p = 0.0242), although no statistically significant
between group differences were observed. (C) The EDL muscles of C57Bl/10 and mdx mice in each of the four treatment groups were subjected to
four lengthening contractions and the decline in maximal force was tested using a mixed-effects linear regression model. Maximal force was also
shown to decrease after each subsequent contraction due to the damage incurred by the lengthening contractions. *The overall decline in maximal
force was significantly lower in response to repeated lengthening contractions in the combined treatment group relative to vehicle control.
doi:10.1371/journal.pone.0066617.g001

Rotarod apparatus (UgoBasile, VA, Italy) for 2 days prior to data
collection on day 3. Each trial was performed twice per day,
consecutively for 3 days, with a 2 h interval between sessions
before and after the three-month pre-clinical trial. The latency to
fall score was measured six times per trial for each mouse. The
average latency to fall score was then calculated using data from
each of the six trials and was expressed in seconds for each mouse
tested.

administered via oral drops. Each of the treatment regimens was
administered 5 days per week (Monday-Friday) for 3 months. All
functional, behavioral and histological assessments were acquired
and analyzed in a blinded fashion.

Treadmill Exercise
Treadmill exercise was performed on all mice before and during
the 3-month treatment regimen to unmask the mild dystrophic
phenotype of mdx mice based on previous studies demonstrating an
exacerbation of the dystrophic phenotype in mdx mice with
treadmill exercise [13]. All mice were exercised on a horizontal
treadmill (Columbus Instruments, Columbus, OH) 2 days per
week at a treadmill speed of 12 m/min for 30 min per day in
accordance to the Treat NMD standard operating procedure for
preclinical studies using mdx mice (http://www.treat-nmd.eu/
downloads/file/sops/dmd/MDX/DMD_M.2.1.001.pdf). All exercise was performed between 0800 h and 1200 h and completed
1–2 days prior to functional testing.

Grip Strength Testing
Forelimb and hindlimb grip strength was assessed at the
beginning and end of the trial in order to evaluate changes in
motor strength in response to the different treatment regimens.
Forelimb and hindlimb grip strength measurements were
performed using a Grip Strength Meter (Columbus Instruments,
Columbus, OH). Grip strength was quantified by averaging five
successful hindlimb and forelimb strength measurements each
recorded within a 2 min time interval in order to calculate
absolute grip strength. All strength measures were then normalized
to individual animal body mass to calculate normalized grip
strength, expressed in kgf/kg, as described previously [16].

Rotarod Testing
Rotarod testing was performed according to methods we have
described previously [14,15,16]. Briefly, mice were trained on a
PLOS ONE | www.plosone.org
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Table 2. Effect of treatment on functional outcomes following 3 months of treatment.

Vehicle

LANZO

PRED

Combined

Measurement

N

Mean ± SEM

N

Mean ± SEM

N

Mean ± SEM

N

Mean ± SEM

Overall
p-value

Significantly different
means

Body weight (g)*

10

24.960.63

12

24.060.33

12

24.160.33

12

23.960.54

NS

None

0.0368

ac

ac

Forelimb GSM (kgf)* 10

0.10260.003

12

0.10160.002

12

0.10260.003

12

0.11360.003

Hindlimb GSM (kgf) 10

0.18560.004

12

0.19860.004

12

0.19260.003

12

0.20460.003c

0.0099

c

Normalized Forelimb 10
GSM (kgf/kg)*

4.28260.144

12

4.27960.120

12

4.22560.130

12

4.55360.120

NS

None

Normalized Hindlimb 10
GSM (kgf/kg)*

7.98360.240

12

8.42060.208

12

7.85560.209

12

8.06560.217

NS

None

LANZO vs. Combined
(p = 0.049)
Veh vs. Combined
(p = 0.009)

Footnotes:
*Baseline measurements were significantly different between groups and thus baseline measurements were used as a covariate in ANOVA models.
doi:10.1371/journal.pone.0066617.t002

frozen in isopentane chilled in liquid nitrogen. Sections were
imaged using a Nikon E800 microscope and taken at a
magnification of 20x. Five non-overlapping field images representative of the overall tissue histology were captured using digital
imaging computer software (Olympus C.A.S.T. Stereology System, Center Valley, PA). All of the digital images were uploaded
into Image J Software (NIH, Bethesda, MD) for analysis using a
cell counter software plug-in. The number of inflammatory foci
and fibrosis were assessed in the diaphragm between treatment
groups. Diaphragm fibrosis was assessed by use of Picro sirius red
staining with a Weigert’s haematoxylin nuclear counter stain on
diaphragm cross-sections. In gastrocnemius cross-sections the total
number of degenerating, regenerating and inflammatory foci per
field were quantified in order to assess differences between
treatment groups. The average number of fibers sampled in the
5 non-overlapping cross-sections was 170, with a range of 88–300
fibers per field. Fibers displaying a loss of striations/homogenous
appearance of fiber contents were counted as degenerating fibers.

Behavioral Activity Measurement
Open field behavioral activity was measured using an open field
Digiscan apparatus (Omnitech Electronics, Columbus, OH) in
order to assess locomotor activity as described previously [16]. All
mice were acclimated 60 min prior to data collection. Outcome
variables included total vertical and horizontal activity, total
distance traveled, movement time, and rest time. Data were
collected every 10 min over a 1 h period before and after the preclinical trial.

Histological Evaluations
At the end of the study, all mice were euthanized via carbon
dioxide exposure, and organ and tissue samples were collected for
histological evaluation. After weighing, a portion of each of the
dissected tissues (i.e., gastrocnemius, EDL, soleus, heart and
spleen) was kept in formalin for H&E staining. The remaining
portion of each tissue was embedded in OCT compound and

Figure 2. Effect of treatment on Rotarod latency to fall. Latency to fall time was measured between treatment groups (n = 12 per group, with
the exception of the vehicle control [n = 10]) via Rotarod testing during the last week of the trial. The data analyzed is an average of six latency to fall
scores where Rotarod testing was performed two times per day for 3 consecutive days after a 24 h acclimation period. Time to fall was compared
between treatment groups using a log-rank test and Kaplan-Meier estimate. Although the LANZO and combined treatment groups displayed a
greater median time to fall, no statistically significant differences were detected between treatment groups.
doi:10.1371/journal.pone.0066617.g002
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Table 3. Effect of treatment on open field behavioral (locomotor) activity.

Vehicle

LANZO

PRED

Combined

Post-Treatment
Measurement

N

Median (range)

N

Median (range)

N

Median (range)

N

Median (range)

Overall pvalue

HACTV

10

1213 (785–2212)

12

1266 (772–2021)

12

1266 (995–1963)

12

1096 (402–1963)

NS

TOTDIST

10

251 (155–841)

12

273 (114–628)

12

253 (182–516)

12

213 (64–516)

NS

MOVTIME

10

27 (16–101)

12

29 (11–74)

12

28 (20–64)

12

25 (9–64)

NS

RESTIME

10

573 (499–584)

12

571 (526–589)

12

573 (536–580)

12

576 (536–591)

NS

VACTV

10

14 (10–88)

12

14 (7–37)

12

21 (12–47)

12

21 (3–47)

NS

Legend:
HACTV = total horizontal activity; TOTDIST = total movement distance; MOVTIME = total movement time; RESTIME = total rest time; VACTV = total vertical activity.
doi:10.1371/journal.pone.0066617.t003

Blood for creatine kinase (CK) assay was collected by cardiac
puncture into preservative-free Eppendorf tubes immediately after
animal sacrifice. Blood serum was isolated by centrifugation for
CK activity determination by standard enzymatic assay preformed
according to the manufacturer’s instructions (CK10, Fisher
Scientific). Enzymatic activity was calculated by measuring light
absorption on a spectrometer set at 340 nm every minute for a
total of 2 min at 37uC. All serum samples were run in duplicate for
CK quantification.

normality (e.g. baseline open field measures), a non-parametric
Kruskal-Wallis test was used to compare medians among groups.
Data displaying significant p-values from the Kruskal-Wallis was
further analyzed for between group differences via Wilcoxon ranksum pair-wise comparisons. Resulting p-values were again
adjusted for multiple comparisons using the Sidak method.
Rotarod data was analyzed as a time to fall analysis using a log
rank test of the equality of survivor functions between treatment
groups. CK values were log-transformed to conform to normality.
Histology measurements were compared between treatment
groups using Poisson regression models for count data where
appropriate. Longitudinal analysis of the repeated lengthening
contractions used a mixed-effects linear regression model where
mouse ID# was a random coefficient and where each treatment
was compared to control only. Nominal statistical significance was
set at a = 0.05.

In Vitro Force Measurement

Results

In vitro force measurements were performed according to
methods we have described previously [17]. Briefly, the EDL of
the right hindlimb was surgically removed and placed vertically in
25uC bath containing buffered mammalian Ringer solution and
aerated with 95% O2–5% CO2. Muscles were secured to the lever
arm of a servomotor/force transducer by the distal tendon (model
305B, Aurora Scientific) and the proximal tendon was connected
to a stationary post in the bath. The muscles were stimulated at
optimal length for 300 ms. Increasing electrode frequencies were
used until a plateau was achieved and recorded as the maximal
force. Specific force was obtained by dividing the maximal force
by the EDL cross sectional area. Additionally, the muscles were
subjected to a protocol of 4 lengthening contractions separated by
1 min intervals of rest. The muscles were lengthened over 10% of
their length.

Effect on Muscle and Organ Weight

Regenerating fibers were counted as fibers with basophilic
cytoplasm, large peripheral, or central nuclei with prominent
nucleoli. All cell counts per image field (degenerating/regenerating
fibers and inflammatory foci) were assessed in a blinded manner as
described previously [16].

Creatine Kinase Determination

Mice in each of the treatment groups gained body mass over the
course of this three-month pre-clinical trial (Table S1). Although
mice were randomly assigned to treatment groups, there were
statistically significant between-group differences in mean body
mass prior to treatment (not shown). Due to these differences,
baseline body mass was used as a covariate when comparing
between group differences in mean body mass at the end of the
three-month preclinical trial. Upon analysis, no significant
differences in mean body mass between groups were observed at
trial’s end (Tables 1 & S1). When comparing changes in mean
body mass over the length of the trial, mice in the LANZO,
prednisolone and combined treatment groups gained significantly
less weight over the course of the study relative to the vehicle
control (percent body mass gain relative to vehicle control:
LANZO -23%, PRED 227%, Combined 236%) (Table S1).
These findings support the efficacy of the treatment regimens as
they are in agreement with our previous observations that
untreated mdx mice gain more weight overtime than wild type
littermate controls [14]. Muscle and organ weights were recorded
at time of sacrifice. No significant differences in average
gastrocnemius, soleus, EDL, or heart mass were observed between
treatment groups (Table 1). A significantly lower mean spleen mass
was observed in mice in the prednisolone and combined treatment
groups relative to the vehicle control (spleen mass at time of
sacrifice relative to vehicle control: PRED 222%, Combined
228%). Mice in the vehicle control and LANZO groups displayed
similar spleen weights at time of sacrifice (94.364.2 and

Statistical Analysis
All analyses were performed using Stata V11 (College Station,
TX). Results are represented as mean6SEM or median (range),
where appropriate. Normality was assessed for each measurement
using the Shapiro-Wilk normality test. For measurements meeting
the assumption normality, analysis of variance (ANOVA) was used
to compare means among groups (vehicle control, LANZO
treatment, prednisolone treatment and combined treatment).
Post-hoc pairwise group comparisons were performed where
ANOVA models showed a significant F-test and the resulting
group p-values were adjusted for multiple comparisons using the
Sidak method. For measurements not meeting the assumption of
PLOS ONE | www.plosone.org
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Figure 3. Effect of treatment on histological parameters between treatment groups at 20 weeks. H&E staining was performed on
gastrocnemius muscle cross sections. Muscle histology (number of degenerating, regenerating and inflammatory foci per field) was averaged over
five representative fields of non-overlapping fiber cross-sections (A–C). (A) Average number of degenerating fibers per field. (B) Average number of
regenerating fibers per field. (C) Average number of inflammatory cell foci per field per group. (D–G) Representative gastrocnemius muscle cross
sectional fields taken from vehicle control (D), LANZO-treated (E), prednisolone-treated (F), and combined treatment (G) groups.
doi:10.1371/journal.pone.0066617.g003

95.066.0 mg, respectively) (Table 1). Additionally, the combined
treatment group did not show a significant difference in mean
spleen mass relative to the prednisolone treatment group (Table 1).

Effect of Treatment on Behavioral Outcomes
No statistically significant differences in post-treatment or
changes in open field behavioral activity measures, including:
total distance traveled, vertical activity, horizontal activity,
movement time and rest time were detected between treatment
groups (Table 3). Of note, there were no significant differences in
baseline open field behavioral activity measurements (data not
shown). There were no significant differences in median latency to
fall time by Rotarod between groups at trial’s end by log-rank test
(p = 0.115) (Fig. 2). However, mice in the LANZO treatment
group did display a higher median latency to fall score relative to
the vehicle control. Mice in the combined treatment group
displayed similar latency to fall scores as mice in the vehicle
control group, while mice in the prednisolone treatment group
displayed the lowest latency to fall score.

Effect of Treatment on Muscle Function
In vitro maximal and specific muscle force was compared
between treatment groups. Maximal force was not significantly
different among treatment groups (p = 0.179), although there was
a non-significant 13% and 15% increase in maximal force in
LANZO and combined treatment groups, respectively, relative to
the vehicle control group at the trial’s end (Fig. 1 A). Maximal
force was not different between normal C57Bl/10 mice and
vehicle treated mdx mice, which is consistent with previous reports
[18]. However, there was a distinct reduction in EDL specific force
in mdx mice in comparison to C57Bl/10 mice (Fig. 1 B), which is
consistent with previous reports of reduced specific force in mdx
mice [19]. In vitro specific force was significantly different among
treatment groups (p,0.05). Although no statistically significant
between group differences were observed, mice in the LANZO
and combined treatment groups displayed a 19% and 18%
increase in specific force, respectively, relative to the vehicle
control at the trial’s end (Fig. 1 B). Isolated EDL muscle was
additionally subjected to four lengthening contractions in order to
assess declines in maximal muscle force in response to repeated
eccentric stretching. Declines in maximal EDL force in response to
lengthening contractions were significantly less in the combined
treatment group relative to vehicle control (Fig. 1 C).
Forelimb and hindlimb grip strength testing was performed
before and after the 3-month study and on untreated (nonexercised) C57Bl/10 mice, which served as a normal reference
group. In mdx treatment groups, absolute forelimb grip strength
was significantly different between groups prior to treatment (not
shown). Therefore, baseline absolute forelimb grip strength was
used as a covariate in ANCOVA models when determining
between group differences in post-study grip strength measures. At
the end of the pre-clinical trial, mice in the combined treatment
group displayed a 10% higher absolute hindlimb grip strength
relative to the vehicle control (p,0.01) (Table 2). Additionally,
mice in the combined treatment group displayed a 12% higher
absolute forelimb grip strength relative to mice in the LANZO
treatment group (p,0.05). No other statistically significant
between group differences in grip strength at the time of sacrifice
were observed. There were no statistically significant differences in
mean change in absolute forelimb or hindlimb grip strength (post
minus pre values) between treatment groups (Table S1). Normalized grip strength did not display statistically significant differences
between groups at trial’s end (Table 2). However, over the 3month course of the study, mice in the prednisolone and combined
treatment groups displayed an attenuated decline in normalized
forelimb grip strength relative to the vehicle control (change in
normalized forelimb grip strength relative to vehicle control:
PRED +60% and combined +57%; p,0.05). Additionally, mice in
the combined treatment group displayed a 44% attenuation in the
decline of normalized hindlimb grip strength relative to the vehicle
control at the trial’s end (p,0.05; Table S1).

PLOS ONE | www.plosone.org

Effect of Treatment on Muscle Histology and Creatine
Kinase
Muscle histology was performed on gastrocnemius cross sections
at time of sacrifice to quantify the number of degenerating/
regenerating fibers and the number of inflammatory foci.
Histology was compared between groups via Poisson regression
on the median for count data, where appropriate. A decrease in
the median number of degenerating fibers was observed in the
prednisolone and combined treatment groups relative to mice
receiving vehicle control (percent decrease in median number of
degenerating fibers relative to vehicle: PRED 283%, p,0.01;
combined: 250%, p,0.05) and LANZO treatment groups
(Table 4; Fig. 3 A). No significant differences in the number of
regenerating fibers were observed between any of the treatment
groups (Table 4; Fig. 3 B). The median number of inflammatory
foci per gastrocnemius cross sectional field was reduced in all three
of the treatment groups relative to vehicle control (decrease in
inflammatory foci per field relative to vehicle control: LANZO
236%, p,0.01; PRED 236%, p,0.05; combined 255%
p,0.001) (Table 4; Fig. 3 C). Mice in the combined treatment
group displayed the lowest amount of median inflammatory foci
per gastrocnemius cross sectional field. Representative H&E
stained gastrocnemius cross-sections are displayed in Fig. 3 D–G.
There were no significant between group differences in the
mean number of inflammatory foci or fibrosis per diaphragm cross
sectional field. However, the mean number of inflammatory foci
was decreased ,22% in the diaphragm of mice receiving
combined treatment relative to vehicle control (Table 4). Additionally, a non-significant ,14% decrease in the mean number of
fibrotic regions was observed in the diaphragm of mice in the
combined treatment group relative to vehicle control (Table 4).
Sera was obtained via cardiac venipuncture at time of sacrifice
and analyzed in duplicate via enzymatic assay. Mice in the
combined treatment group displayed a ,64% reduction in mean
serum CK relative to vehicle control (p,0.05) (Fig. 4). Mice in the
prednisolone treatment group displayed a ,54% reduction in
mean serum CK relative to untreated control, but this did not
reach statistical significance. No significant differences in mean
serum CK were observed between any of the other treatment
groups. However, upon removal of two outliers in the Vehicle and
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NONE
18.963.7
5
18.563.9
Footnotes:
**Histology compared between groups using Poisson regression.
doi:10.1371/journal.pone.0066617.t004

5
Fibrosis (diaphragm)
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Skeletal muscle excitability is regulated by ionic gradients.
Following membrane depolarization, activation of the Na+/K+ATPase proton pump restores resting Na+ and K+ gradients and
helps maintain muscle excitability for repeated contractions [20].
Due to alterations in membrane stability and ion conductivity in
dystrophic muscle, we sought to investigate the effects of the
proton pump inhibitor LANZO on the dystrophic phenotype in
mdx mice. The main finding of our study was that combined
LANZO and prednisolone treatment improved some components
of the dystrophic phenotype in dystrophin deficient mdx mice.
Attenuation of the dystrophic phenotype in the combined
treatment group relative to the vehicle control was indicated by
observations of: 1) a decreased number of degenerating fibers and
inflammatory foci per gastrocnemius cross sectional field; 2)
attenuated declines in normalized forelimb and hindlimb grip
strength; 3) attenuated declines in maximal in vitro EDL force in
response to repeated lengthening contractions. LANZO administration decreased declines in body mass and reduced the number
of muscle inflammatory foci. LANZO administration also
appeared to improve specific and maximal gastrocnemius muscle
force, although this did not reach statistical significance. The
effects of LANZO and prednisolone were not additive, mice in the
combined treatment group did display greater improvements in
muscle force in response to repeated eccentric contractions and a
reduced number of muscle inflammatory foci relative to the
prednisolone treatment group.
The beneficial effects of dual LANZO and prednisolone
administration are likely multifold. LANZO belongs to a class of
proton pump inhibitors (PPIs) that become active in weakly acidic
environments. LANZO has been suggested to bind to other classes
of proton pumps, including the Na+/K+-ATPase [21]. However,
the ability of the dose of LANZO used in this study to induce
in vivo inhibition of proton pumps extragastrically has not been
thoroughly investigated. We hypothesize that the mechanisms by
which combined LANZO and prednisolone treatment improve
the dystrophic phenotype in mdx mice may include: 1) reduced
inflammatory cell recruitment to the skeletal muscle; 2) altered ion
conductivity of skeletal muscle Na+/K+-ATPase and chloride ion
channels; 3) decreased apoptotic signaling cascades promoting
myonecrosis.
Off-label use of LANZO has been more thoroughly investigated
in the treatment of cancer, wherein LANZO has been suggested to
have anti-inflammatory and anti-metastatic effects. De Milito et al.
observed that PPI administration promotes B cell apoptosis in
acute B cell lymphatic leukemia via altering tumor lysosomes and
extracellular pH [22]. The anti-metastatic effects of LANZO
administration are also supported by a Phase I/II trial by
Spungnini et al. who observed improved tumor outcomes in
animals receiving combined treatment of LANZO and chemotherapeutics [23]. The ability of LANZO to inhibit tumor
metastasis is suggested to occur via LANZO-mediated inhibition
of V-ATPases, which are upregulated in metastatic cancers and
contribute to maintenance of the metastatic tumor microenvironment and the Warburg effect via proton extrusion [23]. Both Vand H+/K+-ATPases are inhibited by disulfide binding to cysteine
residues on their a subunits [24]. This supports the role of
LANZO action on various classes of ATPases. Like the H+/K+ATPase, the Na+/K+-ATPase is a class IIC P-type ATPase which
is expressed in skeletal muscle. LANZO has also been observed to

5
24.269.6
5

46615
6
57617
6
56616
6
6
Inflammatory foci per field
(diaphragm)

59616

5 (3–7)c
5
7 (3–17)b
5
6
Inflammatory foci per field
(gastrocnemius) **

11 (6–40)

5

7 (5–10)a

0 (0–17)
5
8 (3–25)
5
6
Regenerating fibers per field
(gastrocnemius) **

5 (0–17)

6

22.064.7

NONE

Veh vs. LANZO (p = 0.008); bVeh vs. PRED (p = 0.012); cVeh vs. Combined (p,0.001)
a

ac

NONE
3 (1–10)
5

5

6 (1–7)c,

ac

b

Discussion

Degenerating fibers per field
(gastrocnemius)**

12 (3–13)

5

12 (3–33)

5

ab

2 (1–9)b,

Median (Range)
N
Median (Range)
N
N
Median (Range)
N

Median (Range)

Combined
PRED
LANZO
Vehicle
Measurement

Table 4. Effect of treatment on histological outcomes following 3 months of treatment.

Significantly different means/medians

Veh vs. PRED (p = 0.002); cVeh vs. Combined (p = 0.018);
LANZO vs. Combined (p = 0.005)

ab

LANZO vs. PRED (p = 0.001);

LANZO groups, no statistical differences remained among
treatment groups.
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Figure 4. Effect of treatment on creatine kinase. Serum CK levels at time of sacrifice between vehicle control (n = 9), LANZO (n = 11),
prednisolone (n = 12), and combined treatment (n = 11) groups. There were three mice for which a cardiac venipuncture was not obtained due to
technical difficulties. All sera was obtained via cardiac venipuncture and analyzed in duplicate via enzymatic assay. Statistical analysis was performed
on log-transformed data. Upon removal of two outliers in the vehicle and LANZO groups, no statistical differences remained among treatment
groups (not shown).
doi:10.1371/journal.pone.0066617.g004

inhibit the Na+/K+-ATPase, albeit at a higher IC50 than it inhibits
the H+/K+-ATPase [21]. The H+/K+-ATPase and Na+/K+ATPase pumps are highly homologous and display species
conservation in their catalytic a subunit cysteine residues (LANZO
binding sites) [25]. In the skeletal muscle, the Na+/K+-ATPase
pump resides at the sarcolemma and t-tubule system, where it
functions to restore membrane potential following contraction via
ATP-mediated Na+ extrusion and K+ import. It is conceivable that
LANZO may improve components of the dystrophic phenotype
by binding to the skeletal muscle Na+/K+-ATPase and altering ion
influx. Dystrophic fibers display an accumulation of intracellular
calcium, which promotes myonecrosis [7] and reduces skeletal
muscle force [26] via altering excitation-relaxation coupling [27].
Dietary NaCl supplementation has been shown to attenuate
myofiber necrosis and reduce serum CK concentrations in mdx
mice [8]. As predicted by the Nernst equation, an increase in
intracellular Na+ that may occur via LANZO-mediated Na+/K+
ATPase pump inhibition may reduce intracellular Ca2+ influx. A
reduction in intracellular Ca2+ would thus reduce myofiber lysis
and improve the dystrophic phenotype in mdx mice. Such
alterations in Ca2+ ionic flux due to LANZO administration
may also affect macrophage polarization and NO production as
macrophage production of NO is enhanced in the presence of
Ca2+ ionophores [28]. Contrary to this hypothesis of Na+ mediated Ca2+ extrusion, an increase in intracellular Na+ levels
may increase intracellular Ca2+ by decreasing the electrogenic
potential of the Na+/Ca2+ exchanger. This is supported by
findings from Allen et al. who observed that elevated intercellular
Na+ promotes Ca2+ influx in myocytes [29]. Thus, the beneficial
effects of combined LANZO and prednisolone administration may
occur by mechanisms other than regulation of Na+ and Ca2+
influx and warrant further investigation. In dystrophic fibers,
decreases in membrane resistivity increase membrane conductivity
of a variety of ions including Cl2 [3]. Increases in Cl2
PLOS ONE | www.plosone.org

conductance alter skeletal muscle membrane excitability [30].
Increased Cl2 ion flux in fibroblasts surrounding myofibers of mdx
mice has also been shown to worsen the dystrophic phenotype
[31]. LANZO has been observed to inhibit gastric chloride ion
channels [32]. Our findings of an attenuated decline in in vitro
muscle force in response to repeated eccentric contractions in mice
given combined LANZO and prednisolone treatment could thus
be due to altered Cl2, Na+ or Ca2+ conductance and subsequent
enhanced muscle excitability in response to LANZO administration. Declines in in vitro muscle force in response to eccentric
contractions have been attributed to failure in E–C coupling and
thus our findings support a potential role for LANZO in
improving dystrophic muscle excitability [33]. Further research
investigating the kinetics of oral LANZO administration on
skeletal muscle ATPases will help elucidate the potential mechanisms of LANZO action.
Another putative beneficial effect of LANZO on the dystrophic
phenotype may be due to its anti-inflammatory properties.
Macrophage pre-treatment with LANZO decreases nitric oxide
(NO) synthesis and cell viability in response to stimulation by LPS
[34]. Further, pretreatment of monocytes with LANZO has been
shown to decrease LPS-induced TNFa and IL-1b expression via
decreasing IkB-a and ERK phosphorylation [35]. A similar PPI,
omeprazole, has been shown to decrease neutrophil chemotaxis
and ROS production [36]. Further, omeprazole has been shown
to decrease peripheral blood neutrophil phagocytic activity and
oxidation 4 hours after oral administration in healthy human
subjects [11]. Since the mechanisms of actions between different
classes of PPI are similar, we hypothesize that oral LANZO
administration may attenuate the dystrophic phenotype in mdx
mice by reducing neutrophil recruitment and respiratory burst and
by skewing of muscle macrophages away from a proinflammatory
M1 macrophage phenotype. This is supported as populations of
iNOS expressing muscle macrophages have been suggested to
9
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contribute to muscle cell lysis in mdx mice and shifts in muscle
macrophage activation from a proinflammatory to anti-inflammatory/regenerative phenotype improve dystrophic pathology
[12]. Further, depletion of neutrophils has been shown to
attenuate components of the dystrophic phenotype in mdx mice
[37].
LANZO irreversibly binds to cysteine moieties and its serum
half-life is ,1.5 hours. Due to the rapid catabolism of LANZO by
the gastric environment and metabolism by the liver, the effects of
LANZO administration are likely less pronounced in the skeletal
muscle relative to the gastric epithelia. Therefore, we hypothesize
that dual LANZO and prednisolone administration was efficacious
due to partial inhibition of Na+/K+-ATPase pumps and chloride
channels. The beneficial effects of dual LANZO and prednisolone
administration were not additive. Glucocorticoids, like prednisolone, upregulate Na+/K+-ATPases [38]. We thus believe that the
combined treatment was more efficacious than prednisolone
administration alone because of the ability of LANZO to reduce
elevated skeletal muscle Na+/K+-ATPase activity, due to prednisolone treatment, and further decreasing neutrophil and macrophage cytoxcity. Additional investigation of the dose-dependent
effects of combined LANZO and prednisolone treatment are thus
warranted as higher doses of LANZO may be more efficacious in
the treatment of dystrophic pathology.

Conclusions
Our findings suggest that combined LANZO and prednisolone
treatment provides slightly improved therapeutic efficacy in
treating the dystrophic skeletal muscle phenotype in mdx mice
relative to prednisolone treatment alone. Complications of DMD
may include other symptoms that may be improved with LANZO
administration, such as delayed gastric emptying, gastric inflammation, smooth muscle fibrosis and dilation [39,40]. Due to the
therapeutic benefits of LANZO on the dystrophic phenotype,
future investigation of the clinical efficacy of dual LANZO and
prednisolone administration in human trials may be warranted.
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